evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract
10848,GENE_BACKGROUND,,"The CCND3 gene encodes Cyclin D3, a protein that couples extracellular growth signaling to entry into the cell cycle through activating cyclin-dependent kinase 4 (CDK4) and CDK6 (PMID: 8114739). Upon complexing with CCND1, CDK4 and CDK6 phosphorylates and inactivates retinoblastoma (RB), thus leading to the induction of a gene expression program regulated by the E2F family of transcription factors (PMID: 12432268). However, CCND3 (like CCND1 and CCND2) is not essential for entry into the cell cycle (PMID: 15315760). Like Cyclin D1, Cyclin D3 is also known to inhibit the activity of androgen receptor (AR) and peroxisome proliferator activator receptor-γ (PPAR-γ). Unlike CCND1, CCND3 is rarely amplified in human cancers (PMID: 21734724). Given the strong link between aberrant CDK4/6 activity and cancer cell proliferation, therapeutics targeting CDK4/6 have been intensely investigated. In 2015, the first CDK4/6 inhibitor was FDA-approved for the treatment of breast cancer (fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm432886; June 2015); other inhibitors are currently in clinical trials to treat tumors with CCND1 amplification and other mutations that impact CDK4/6 activity (PMID: 24795392). However, their utility in treating cancers with CCND3 amplification specifically has not been investigated.",,2017-03-01,,896,CCND3,cyclin D3,True,ENST00000372991,NM_001760.3,False,8114739,"Identification of G1 kinase activity for cdk6, a novel cyclin D partner.",Molecular and cellular biology,0001-03-01,14,3,2077-86,Meyerson M et al,,,0001-03-01,,12432268,Cycling to cancer with cyclin D1.,Cancer biology &amp; therapy,2018-05-01T20:02:00,True,3,226-31,Diehl JA,,,0001-05-01,,15315760,Mouse development and cell proliferation in the absence of D-cyclins.,Cell,2018-08-20T20:04:00,118,4,477-91,Kozar K et al,,,0001-08-20,,24795392,Molecular pathways: CDK4 inhibitors for cancer therapy.,Clinical cancer research : an official journal of the American Association for Cancer Research,2018-07-01T20:14:00,20,13,3379-83,Dickson MA,doi: 10.1158/1078-0432.CCR-13-1551,,0001-07-01,,21734724,Cyclin D as a therapeutic target in cancer.,Nature reviews. Cancer,2018-07-07T20:11:00,11,8,558-72,Musgrove EA et al,doi: 10.1038/nrc3090,,0001-07-07,
10847,GENE_SUMMARY,,CCND3 encodes a protein that regulates cell cycle progression. Amplification of CCND3 is found in a diverse range of cancers.,,2017-03-01,,896,CCND3,cyclin D3,True,ENST00000372991,NM_001760.3,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
